Once-daily raltegravir: 96-week results from the ONCEMRK study
1 October 2017. Related: Conference reports, Antiretrovirals.
Antiretrovirals
Gilead uses voucher to speed FDA review of bictegravir
1 October 2017. Related: Antiretrovirals.
HIV pipeline drugs: IAS 2017 update
10 August 2017. Related: Conference reports, Antiretrovirals.
Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF
10 August 2017. Related: Conference reports, Antiretrovirals.
Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART
10 August 2017. Related: Conference reports, Antiretrovirals.
Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results
10 August 2017. Related: Conference reports, Antiretrovirals.
Reduced-dose darunavir is safe and effective in switch study
10 August 2017. Related: Conference reports, Antiretrovirals.
MK-8591: further compelling early results for both treatment and prevention
10 August 2017. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.
First dolutegravir-based generic FDC gets FDA tentative approval
10 August 2017. Related: Antiretrovirals, Treatment access.
FDA grant priority review for ibalizumab
10 August 2017. Related: Antiretrovirals.
HIV pipeline report 2017
20 July 2017. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
HIV pipeline 2017: full version
20 July 2017. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
HIV pipeline 2017: summary version
20 July 2017. Related: Supplements, Pipeline report, Antiretrovirals.
HIV pipeline 2017: Update from IAS Paris
20 July 2017. Related: Supplements, Pipeline report, Antiretrovirals.
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs
26 June 2017. Related: Treatment alerts, Antiretrovirals, Side effects.
Dolutegravir pharmacokinetics in pregnancy
26 June 2017. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
High rates of of undocumented efavirenz-related side effects in Uganda
26 June 2017. Related: Conference reports, Antiretrovirals, Side effects.
Increased risk of ART failure after low-level viraemia in a large South African cohort
26 June 2017. Related: Conference reports, Antiretrovirals.
Option B+ Malawi
26 June 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
Dolutegravir/rilpivirine submitted to EMA and FDA as oral two-drug maintenance combination
26 June 2017. Related: Antiretrovirals.
Bictegravir/FTC/TAF: new once-daily integrase-based FDC submitted to US FDA
26 June 2017. Related: Antiretrovirals.
FDA updates cobicistat and Stribild labels: interactions with systemic, inhaled, nasal and ophthalmic corticosteriods
26 June 2017. Related: Antiretrovirals, PK and drug interactions.
Drop in HIV incidence in gay men: frequent testing, early ART and PrEP
24 April 2017. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Prompt/early ART: Dean Street pilot project reports 75% uptake
24 April 2017. Related: Conference reports, Antiretrovirals.
Other selections and webcasts
24 April 2017. Related: Conference reports, Antiretrovirals, Coinfections and complications, Hepatitis coinfection, Cure-related research.
Dose reduction potential of nanoparticle ARV formulations confirmed in humans
24 April 2017. Related: Conference reports, Antiretrovirals.
VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding
24 April 2017. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants
24 April 2017. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Tenofovir alafenamide exposure is modestly higher in children than adults
24 April 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence
24 April 2017. Related: Conference reports, Antiretrovirals, Drug resistance.
Increased risk of IRIS with integrase inhibitors reported in two studies
24 April 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Coinfections and complications.
Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor
27 February 2017. Related: Conference reports, Antiretrovirals, PK and drug interactions.
New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study
27 February 2017. Related: Conference reports, Antiretrovirals.
NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV
27 February 2017. Related: Conference reports, Antiretrovirals.
Dolutegravir exposure increases when fixed dose combination tablets are crushed
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics, safety and efficacy of dolutegravir in very young children
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
Adverse pregnancy outcomes and risk factors in the PROMISE trial
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study
27 February 2017. Related: Conference reports, Antiretrovirals, Pregnancy.
Fit for purpose: antiretroviral treatment optimisation Feb 2017
27 February 2017. Related: Conference reports, Fit for purpose, Antiretrovirals.
US Stribild label updated: new indication to include patients age 12 and older
27 February 2017. Related: Antiretrovirals.
Option to take crushed Stribild tablets with food or enteral nutrition
27 February 2017. Related: Antiretrovirals.
ART adherence in first four months predicts long-term viral suppression in 12-year study
27 February 2017. Related: Antiretrovirals.
Effects of ART initiation on human papillomavirus antibody response
27 February 2017. Related: Antiretrovirals, Coinfections and complications.
Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses
29 November 2016. Related: Conference reports, Antiretrovirals.
Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients
29 November 2016. Related: Conference reports, Antiretrovirals.
Once-weekly albuvirtide infusion: early results of T-20-like compound
29 November 2016. Related: Conference reports, Antiretrovirals.
FDA approves maraviroc for children aged two and older
29 November 2016. Related: Antiretrovirals, Paediatric care.
Ibalizumab infusion reduces viral load in people with HIV multi-drug resistance
29 November 2016. Related: Antiretrovirals.
GSK discontinues development of maturation inhibitor BMS-955176
29 November 2016. Related: Antiretrovirals.
Large disparities in costs of antiretrovirals between low- and middle-income countries
1 October 2016. Related: Conference reports, Antiretrovirals, Treatment access.
High death rates among HIV positive women postpartum accessing ARVs
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy.
Higher rates of eye complications in HIV positive people on ART
1 October 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Raltegravir-based third-line ART in children and adolescents
1 October 2016. Related: Conference reports, Antiretrovirals, Paediatric care.
Raltegravir in HIV-exposed neonates
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
First generic TDF/FTC approved in EU
1 October 2016. Related: Antiretrovirals.
Single-pill PI-based combination submitted to EMA
1 October 2016. Related: Antiretrovirals.
Dolutegravir superior to standard dose efavirenz in WHO analysis
1 October 2016. Related: Antiretrovirals.
Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study
1 August 2016. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir at last available: 48 week results from ONCEMRK study
1 August 2016. Related: Conference reports, Antiretrovirals.
Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2
1 August 2016. Related: Conference reports, Antiretrovirals.
Dolutegravir is superior to boosted atazanavir in women in the ARIA study
1 August 2016. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.